Thanks, Neil and Dave. Good morning, everyone. Starting with revenue, we generated revenue of $172 million, up 12.2% year-over-year and above the high end of our guidance range of $164 million to $167 million. Deferred revenue recognized in January from the strong FSA expiration period in late December combined with improving store performance contributed to our strong start to 2023. From a channel perspective retail revenue increased approximately 28%, while e-commerce revenue declined approximately 8% versus Q1 of 2022. For the first quarter, e-commerce represented 36% of our overall business compared to 44% in 2022 and in line with our pre-pandemic channel mix. The decline in e-commerce revenue was in line with our expectations and driven by an intentional reduction in marketing spend by 35% year-over-year, as we bring marketing spend as a percent of revenue back to pre-pandemic levels in the low teens. We expect e-commerce revenue to begin comping positive in H2 of this year as we anniversary the pullbacks we've made in marketing spend and begin to increase marketing spend dollars year-over-year. We finished Q1 2023 with 204 stores, an increase of 35 stores and an increase in our store count of approximately 21%, which compares favorably to retail revenue of about 28% year-over-year. Retail productivity in Q1 was 103% versus the same period last year. From a customer perspective, we finished the quarter with 2.29 million active customers an increase of 2.5% versus the same period a year ago, and our average revenue per customer increased 8.4% year-over-year to $270. It's worth noting that our revenue growth follows a similar pattern to our growth in active customers, where active customers are increasing in retail driven by new store openings and decreasing in our e-commerce channel as we rebalance marketing spend. We're pleased with our increase in average revenue per customer, which was driven by a few factors including an increase in Progressive as a percentage of our business mix, and continued ramping of both contact lens and eye exam sales. Progressives represented 22.9% of total prescription glasses sold in Q1 2023, up from 20.8% when compared to the first quarter of 2022. This is still well below the market average of approximately 40%, leaving a substantial runway for product category growth. Progressives are also our highest gross margin and highest price point product, starting at $295. We continue to make progress on our move into holistic Vision Care as we evolve from a glass only brand into one that offers glasses, contact and eye exams to customers. From Q1 2022 to Q1 2023, contact lenses have increased from 7% to 7.7% of our business mix. Over the same period, eyecare has increased from approximately 2% to 3.8% of our business mix. Contacts and eye exams both represent large opportunities for future growth, and we remain well underpenetrated for sales of these products, as a percent of revenue versus other national optical retailers. As a reminder, contact lenses and eye exams each represent $10 billion-plus portion of the $76 billion US optical industry. Moving on to gross margin. As a reminder, our gross margin accounts for a range of costs including frames, lenses, optical labs, customer shipping, optometrist salaries, store rent and the depreciation of store build-outs. Our gross margin also includes stock-based compensation expense for our optometrists, and optical lab employees. For comparability, I will be speaking to gross margin excluding stock-based compensation. First quarter adjusted gross margin, was 55.2% compared to 58.7% in the year ago period. The year-over-year decrease was driven by strong growth of eye exams and contact lenses, as we evolved into a holistic vision care company, and expand into the large segments of the optical industry. As a reminder, eye exams and contacts have lower gross margin profiles than eyeglasses, but over the medium and long term are accretive to gross margin dollars and allow us to serve all of our customers' eye care needs. Expanding our contact offering, is a core part of scaling our holistic vision care offering and a key driver of growing average revenue per customer. While contact lenses have a lower gross margin percentage compared to our other offerings, their higher purchase frequency and subscription-like purchase cycle are accretive to gross margin dollars. As a reminder, contact lenses represented an estimated $17.8 billion market in 2023 and account for approximately 20%, of a typical optical retailer sales. We also experienced continued year-over-year gross margin deleverage, in two areas that represent the more fixed portion of our cost of goods, retail occupancy and optometrist salaries which are directly linked to our expansion into eye care. Our growth in store count has naturally led to an increase in store rent, and depreciation from store build-outs. We also saw a downward pressure on gross margin year-over-year, from an increase in overall optometry salaries, as we hired optometrists for our new stores and continued the rollout of our Professional Corporation or PC model. As of the end of Q1 2023, we operated with 120 stores, where we engage directly with an optometrist and therefore, recognize both revenue from exams and optometrist salaries. This represents a 74% year-over-year increase from 69 employed and PC exam stores, at the end of the first quarter last year. Many of our 64 PC model stores are ones where we are converting an existing store, with an independent doctor relationship to the PC model and therefore, we had already been recognizing a significant portion of product conversion sales, at our stores from the independent doctor. We believe this ongoing investment in exam capabilities, will benefit the business long term as we benefit from greater control over the customer experience, new eye exam revenue and higher in-store conversion rates. There are a few accretive tailwinds to margin that act to partially offset these dilutive effects. First, we continue to scale our highest-priced and highest gross margin progressive business. In the first quarter, Progressives accounted for approximately 22.9% of our prescription business, which is up from 20.8%, a year ago. Secondly, we continue to scale the portion of our prescription glasses orders that we in-sourced at our two owned optical labs in New York and Nevada. We expect our continued scaling of these facilities to result in continued gross margin benefits along with higher net promoter scores, lower refund rates and faster turnaround times. Shifting gears to SG&A. As a reminder, SG&A for our business includes three main components: salary expense covering our headquarters, customer experience and retail employees; marketing spend including our Home Try-on program and general corporate overhead expenses. Adjusted SG&A excludes the non-cash costs like stock-based compensation expense. Adjusted SG&A in the first quarter was $87.2 million or 50.7% of revenue, down 9.4% when compared to Q1 2022 adjusted SG&A of $96.2 million or 62.8% of revenue. The primary drivers of the decrease in adjusted SG&A, as a percentage of revenue, were lower marketing costs and benefits from the adjustments to our cost structure we implemented in August of last year. Marketing spend for the quarter came in at $20.1 million or 11.7% of revenue. This is down from $31.1 million and 20.3% of revenue in the same period last year. Marketing spend in Q1 2023 was 35% lower year-over-year, which compares to revenue growth of 12.2% year-over-year. Turning now to adjusted EBITDA. In the first quarter we generated adjusted EBITDA of $17.7 million, representing an adjusted EBITDA margin of 10.3%, which compares to adjusted EBITDA of $0.8 million or 0.5% of revenue in the year ago period. This significant year-over-year improvement underscores our commitment and ability to drive profitable growth even in a lower demand environment. Turning now to our balance sheet. We finished the quarter with a strong balance sheet position reflecting $204.3 million in cash, which we will continue to deploy deliberately to support our growth and operations. We also have an undrawn credit facility of $100 million other than $4 million for letters of credit that we can upsize to $175 million. Now to our outlook. At this time, we're maintaining the full year guidance we outlined on our Q4 earnings call on February 28. For 2023, we still expect net revenue growth of approximately 8% to 10%, representing a revenue range of $645 million to $660 million adjusted EBITDA margin of approximately 7.9%, which equates to adjusted EBITDA of approximately $51.5 million at the midpoint of our top line guidance range. Gross margin in the mid-50s as a percent of revenue, 40 new store openings, bringing our total store count to approximately 240 by year-end. We are still forecasting stock-based compensation as a percentage of net revenue in 2023 to be roughly 10% compared with 16% in 2022. Stock-based compensation for both years is above our long-term forecast of low-single-digits as the result of the multiyear equity grants to our co-CEOs in 2021, the majority of which is performance-based and invest based on stock price targets from $47.75 to $103.46. We still anticipate stock-based compensation to normalize to a range of 2% to 4% of net revenue late in 2024. With respect to the second quarter, we're guiding to the following: net revenue of $160 million to $162.5 million or revenue growth of approximately 7% to 9%. For Q2 to-date, we've observed trailing 28-day retail productivity versus 2022 between 99% and 102%. From a bottom-line perspective, we're guiding to adjusted EBITDA of $11 million to $12.5 million, representing adjusted EBITDA margin of approximately 7% to 8%. As noted on our last call, we expect the quarterly progression of our profitability to be more in line with pre-pandemic trends with more of our adjusted EBITDA generated in the first half of the year versus 2022 where we generated the majority of our adjusted EBITDA in the second half of the year. With that, Neil, Dave and I are pleased to take your questions. Operator, please open the line for Q&A.